Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Whitehawk Therapeutics, Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12 | Direct | 38,040 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 21:22 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 38,040 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001878692-26-000003 · form4-06152026_090610.xml · derivative · entry 1 Desai Neil · CIK 0001878692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,040 Underlying: Common Stock · 38,040 shares Expires 2036-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 20:37 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 40,006 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001415889-25-017547 · form4-06172025_080628.xml · derivative · entry 1 Desai Neil · CIK 0001878692 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,006 Underlying: Common Stock · 40,006 shares Expires 2035-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2025. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:55 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 40,000 | $1.71 | $68,316.00 |
DisclosureSEC source: 0001415889-24-022964 · form4-09052024_090938.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,171,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 40,000 shares sold in the price range of $1.63 to $1.82 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| August 05, 2024 Filed Aug 5, 2024 22:49 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 5,652 | $1.34 | $7,594.59 |
DisclosureSEC source: 0001415889-24-020784 · form4-08052024_100800.xml · nonDerivative · entry 3 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,211,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F5 · price: Represents the weighted average share price of an aggregate total of 5,652 shares sold in the price range of $1.31 to $1.38 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 22:49 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 18,933 | $1.41 | $26,705.00 |
DisclosureSEC source: 0001415889-24-020784 · form4-08052024_100800.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,217,195 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 18,933 shares sold in the price range of $1.38 to $1.47 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 22:49 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 15,415 | $1.50 | $23,054.67 |
DisclosureSEC source: 0001415889-24-020784 · form4-08052024_100800.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,236,128 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 15,415 shares sold in the price range of $1.47 to $1.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| July 02, 2024 Filed Jul 2, 2024 22:37 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 8,652 | $1.34 | $11,611.85 |
DisclosureSEC source: 0001415889-24-019045 · form4-07022024_100754.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,251,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 8,652 shares sold in the price range of $1.32 to $1.40 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 22:37 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 31,348 | $1.45 | $45,605.07 |
DisclosureSEC source: 0001415889-24-019045 · form4-07022024_100754.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,260,195 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 31,348 shares sold in the price range of $1.4201 to $1.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 20:25 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 20,225 | $1.77 | $35,745.67 |
DisclosureSEC source: 0001415889-24-015561 · form4-06052024_080618.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,291,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 20,225 shares sold in the price range of $1.73 to $1.81 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:25 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 19,775 | $1.81 | $35,765.07 |
DisclosureSEC source: 0001415889-24-015561 · form4-06052024_080618.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,311,768 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 19,775 shares sold in the price range of $1.79 to $1.89 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| May 01, 2024 Filed May 2, 2024 00:50 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 40,000 | $1.93 | $77,184.00 |
DisclosureSEC source: 0001415889-24-011937 · form4-05022024_120534.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,331,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 40,000 shares sold in the price range of $1.885 to $1.975 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 20:49 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 22,228 | $2.23 | $49,512.87 |
DisclosureSEC source: 0001415889-24-010037 · form4-04032024_080413.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,371,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 22,228 shares sold in the price range of $2.185 to $2.28 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:49 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 17,772 | $2.31 | $41,101.30 |
DisclosureSEC source: 0001415889-24-010037 · form4-04032024_080413.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,393,771 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 17,772 shares sold in the price range of $2.28 to $2.35 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 00:22 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 14,964 | $2.10 | $31,415.42 |
DisclosureSEC source: 0001415889-24-006421 · form4-03052024_120319.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,411,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 14,964 shares sold in the price range of $2.02 to $2.175 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:22 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 27,036 | $1.97 | $53,225.77 |
DisclosureSEC source: 0001415889-24-006421 · form4-03052024_120319.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,426,507 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 27,036 shares sold in the price range of $1.93 to $1.995 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 22:04 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 42,000 | $1.74 | $73,269.00 |
DisclosureSEC source: 0001209191-24-002684 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,453,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 42,000 shares sold in the price range of $1.72 to $1.84 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 00:48 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 42,000 | $2.06 | $86,549.40 |
DisclosureSEC source: 0001209191-24-000254 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,495,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 42,000 shares sold in the price range of $2.00 to $2.10 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 21:04 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 7,037 | $4.82 | $33,914.12 |
DisclosureSEC source: 0001209191-23-057713 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,537,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 7,037 shares sold in the price range of $4.64 to $4.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| December 05, 2023 Filed Dec 5, 2023 23:40 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 15,740 | $5.02 | $78,940.82 |
DisclosureSEC source: 0001209191-23-057545 · doc4.xml · nonDerivative · entry 3 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,544,580 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F5 · price: Represents the weighted average share price of an aggregate total of 15,740 shares sold in the price range of $4.85 to $5.2050 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 23:40 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 10,876 | $5.15 | $55,986.39 |
DisclosureSEC source: 0001209191-23-057545 · doc4.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,560,320 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 10,876 shares sold in the price range of $5.04 to $5.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:40 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 8,347 | $5.14 | $42,881.04 |
DisclosureSEC source: 0001209191-23-057545 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,571,196 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 8,347 shares sold in the price range of $4.97 to $5.34 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| November 02, 2023 Filed Nov 2, 2023 22:45 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 31,662 | $4.46 | $141,104.87 |
DisclosureSEC source: 0001209191-23-054214 · doc4.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,579,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 31,662 shares sold in the price range of $4.35 to $4.61 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 22:45 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 10,338 | $4.32 | $44,644.65 |
DisclosureSEC source: 0001209191-23-054214 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,611,205 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 10,338 shares sold in the price range of $4.275 to $4.36 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| October 03, 2023 Filed Oct 3, 2023 22:51 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 16,431 | $4.10 | $67,303.02 |
DisclosureSEC source: 0001209191-23-051697 · doc4.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,621,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 16,431 shares sold in the price range of $3.97 to $4.32 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 22:51 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 25,569 | $4.37 | $111,698.18 |
DisclosureSEC source: 0001209191-23-051697 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,637,974 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 25,569 shares sold in the price range of $4.17 to $4.88 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 23:05 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 7,111 | $5.29 | $37,637.10 |
DisclosureSEC source: 0001209191-23-048535 · doc4.xml · nonDerivative · entry 3 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,663,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F5 · price: Represents the weighted average share price of an aggregate total of 7,111 shares sold in the price range of $5.24 to $5.45 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 23:05 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 21,000 | $5.63 | $118,316.10 |
DisclosureSEC source: 0001209191-23-048535 · doc4.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,670,654 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 21,000 shares sold in the price range of $5.46 to $5.91 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:05 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 13,889 | $5.97 | $82,872.89 |
DisclosureSEC source: 0001209191-23-048535 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,691,654 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 13,889 shares sold in the price range of $5.80 to $6.37 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 20:22 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 19,290 | $5.20 | $100,250.13 |
DisclosureSEC source: 0001209191-23-044439 · doc4.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,705,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 19,290 shares sold in the price range of $5.09 to $5.30 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:22 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 22,710 | $5.22 | $118,523.49 |
DisclosureSEC source: 0001209191-23-044439 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,724,833 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 22,710 shares sold in the price range of $5.12 to $5.30 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| July 06, 2023 Filed Jul 6, 2023 23:36 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 15,829 | $6.27 | $99,273.16 |
DisclosureSEC source: 0001209191-23-041700 · doc4.xml · nonDerivative · entry 3 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,747,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F5 · price: Represents the weighted average share price of an aggregate total of 15,829 shares sold in the price range of $6.14 to $6.50 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| July 05, 2023 Filed Jul 6, 2023 23:36 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 16,171 | $6.55 | $105,873.15 |
DisclosureSEC source: 0001209191-23-041700 · doc4.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,763,372 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 16,171 shares sold in the price range of $6.41 to $6.715 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 23:36 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 10,000 | $6.64 | $66,446.00 |
DisclosureSEC source: 0001209191-23-041700 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,779,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $6.53 to $6.815 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 00:11 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 7,260 | $8.19 | $59,452.87 |
DisclosureSEC source: 0001209191-23-034888 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,789,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 7,260 shares sold in the price range of $8.02 to $8.34 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| June 05, 2023 Filed Jun 5, 2023 23:01 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 17,315 | $8.11 | $140,417.72 |
DisclosureSEC source: 0001209191-23-034632 · doc4.xml · nonDerivative · entry 3 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,796,803 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F5 · price: Represents the weighted average share price of an aggregate total of 17,315 shares sold in the price range of $7.98 to $8.19 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 23:01 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 12,443 | $7.99 | $99,420.81 |
DisclosureSEC source: 0001209191-23-034632 · doc4.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,814,118 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 12,443 shares sold in the price range of $7.90 to $8.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:01 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 4,982 | $7.92 | $39,468.40 |
DisclosureSEC source: 0001209191-23-034632 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,826,561 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 4,982 shares sold in the price range of $7.82 to $8.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| May 04, 2023 Filed May 5, 2023 20:16 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 2,305 | $7.57 | $17,444.70 |
DisclosureSEC source: 0001209191-23-027672 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,831,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 2,305 shares sold in the price range of $7.47 to $7.75 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| May 03, 2023 Filed May 3, 2023 22:55 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 7,695 | $7.68 | $59,072.98 |
DisclosureSEC source: 0001209191-23-027161 · doc4.xml · nonDerivative · entry 3 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,833,848 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F5 · price: Represents the weighted average share price of an aggregate total of 7,695 shares sold in the price range of $7.46 to $7.83 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| May 02, 2023 Filed May 3, 2023 22:55 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 7,521 | $7.48 | $56,224.74 |
DisclosureSEC source: 0001209191-23-027161 · doc4.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,841,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 7,521 shares sold in the price range of $7.37 to $7.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:55 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 24,479 | $7.80 | $190,894.59 |
DisclosureSEC source: 0001209191-23-027161 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,849,064 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 24,479 shares sold in the price range of $7.68 to $7.855 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 00:45 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 12,212 | $7.09 | $86,616.05 |
DisclosureSEC source: 0001209191-23-023692 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,873,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 12,212 shares sold in the price range of $7.00 to $7.23 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| April 05, 2023 Filed Apr 5, 2023 23:32 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 7,336 | $7.24 | $53,075.96 |
DisclosureSEC source: 0001209191-23-023483 · doc4.xml · nonDerivative · entry 3 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,885,755 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F5 · price: Represents the weighted average share price of an aggregate total of 7,336 shares sold in the price range of $7.20 to $7.37 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| April 04, 2023 Filed Apr 5, 2023 23:32 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 12,869 | $7.30 | $93,981.02 |
DisclosureSEC source: 0001209191-23-023483 · doc4.xml · nonDerivative · entry 2 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,893,091 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 12,869 shares sold in the price range of $7.20 to $7.40 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 23:32 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 9,583 | $7.45 | $71,355.02 |
DisclosureSEC source: 0001209191-23-023483 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,905,960 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 9,583 shares sold in the price range of $7.29 to $7.59 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:05 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $12.31 | $0.00 |
DisclosureSEC source: 0001209191-23-000843 · doc4.xml · derivative · entry 1 Desai Neil · CIK 0001878692 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the option shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 1, 2023. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 00:14 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock option (right to buy) · Derivative | 153,300 | $0.00 Strike: $17.24 | $0.00 |
DisclosureSEC source: 0001209191-22-023349 · doc4.xml · derivative · entry 1 Desai Neil · CIK 0001878692 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,300 Underlying: Common Stock · 153,300 shares Expires 2032-04-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the option shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2022. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 21:34 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | SaleCommon Stock | 3,550 | $20.07 | $71,233.59 |
DisclosureSEC source: 0001209191-22-020582 · doc4.xml · nonDerivative · entry 1 Desai Neil · CIK 0001878692 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,915,543 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on September 20, 2021 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 3,550 shares sold in the price range of $20.00 to $20.09 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 21:05 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock option (right to buy) · Derivative | 125,000 | $0.00 Strike: $27.67 | $0.00 |
DisclosureSEC source: 0000899243-21-035568 · doc4.xml · derivative · entry 1 Desai Neil · CIK 0001878692 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-09-08 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the option shall be fully vested on the four year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 8, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.